Journal
BRAIN INJURY
Volume 32, Issue 2, Pages 257-268Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02699052.2017.1394492
Keywords
Nerve growth factor; neuroinflammation; neurite growth; synaptogenesis; apoptosis; behaviour
Categories
Funding
- Understanding Disease RFA of La Trobe University
- Australian National Health and Medical Research Council
Ask authors/readers for more resources
Objectives: There is evidence that treatment with nerve growth factor (NGF) may reduce neuroinflammation and apoptosis after a traumatic brain injury (TBI). NGF is thought to exert its effects via binding to either TrkA or p75 neurotrophin receptors. This study aimed to investigate the effects of a selective TrkA agonist, gambogic amide (GA), on TBI pathology and outcomes in mice following lateral fluid percussion injury. Methods: Male C57BL/6 mice were given either a TBI or sham injury, and then received subcutaneous injections of either 2 mg/kg of GA or vehicle at 1, 24, and 48 h post-injury. Following behavioural studies, mice were euthanized at 72 h post-injury for analysis of neuroinflammatory, apoptotic, and neurite outgrowth markers. Results: Behavioural testing revealed that GA did not mitigate motor deficits after TBI. TBI caused an increase in cortical and hippocampal expression of several markers of neuroinflammation and apoptosis compared to sham groups. GA treatment did not attenuate these increases in expression, possibly contributed to by our finding of TrkA receptor down-regulation post-TBI. Conclusions: These findings suggest that GA treatment may not be suitable for attenuating TBI pathology and improving outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available